Semaglutide don nau'in ciwon sukari na 2

Semaglutide wani sabon ƙarni ne na GLP-1 (glucagon-like peptide-1), kuma semaglutide wani nau'in sashi ne na dogon lokaci wanda aka haɓaka bisa tushen tsarin liraglutide, wanda ke da sakamako mafi kyau a cikin kula da nau'in ciwon sukari na 2.Novo Nordisk ya kammala karatun 6 Phase IIIa na allurar semaglutide, kuma ya ƙaddamar da sabon aikace-aikacen rajista na magani don allurar mako-mako na semaglutide ga Hukumar Abinci da Magunguna ta Amurka (FDA) a ranar 5 ga Disamba, 2016. An kuma ƙaddamar da Aikace-aikacen Izinin Talla (MAA) ga Hukumar Kula da Magunguna ta Turai (EMA).

Idan aka kwatanta da liraglutide, semaglutide yana da tsayin sarkar aliphatic da ƙara yawan hydrophobicity, amma ana gyara semaglutide tare da ɗan gajeren jerin PEG, kuma ana haɓaka hydrophilicity sosai.Bayan gyare-gyaren PEG, ba wai kawai zai iya ɗaure a kusa da albumin ba, yana rufe wurin da ake kira enzymatic hydrolysis na DPP-4, amma kuma yana rage fitar da koda, tsawaita rayuwar rabin rayuwa, da kuma cimma sakamako na dogon lokaci.